Loading
Golcadomide is a next-generation lenalidomide-like pill that degrades two lymphoma transcription factors far more potently, now in phase 3 with R-CHOP.
Golcadomide is a cereblon E3 ligase modulator (CELMoD): it binds cereblon and recruits the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) for ubiquitination and proteasomal degradation, which downregulates IRF4 and MYC in lymphoma cells and stimulates T cells, far more potently than lenalidomide. In phase 1/2, golcadomide with rituximab gave an ORR of about 50% in relapsed or refractory DLBCL, and with R-CHOP in untreated high-risk DLBCL it produced high complete response rates (ASH 2024). The phase 3 GOLSEEK-1 trial is enrolling patients with IPI 3 to 5 disease to compare golcadomide plus R-CHOP with R-CHOP alone, with readout expected in 2027 to 2028. BMS develops it. It is a next-generation lenalidomide-like pill designed to be added to standard first-line chemotherapy.
Binds cereblon and recruits IKZF1/IKZF3 for ubiquitination and proteasomal degradation; downregulates IRF4/MYC and stimulates T cells. Connects to IKZF1 (Ikaros) and IKZF3 (Aiolos).
1.Golcadomide binds IKZF1 (Ikaros) with one end and an E3 ubiquitin ligase with the other.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Golcadomide" OR ABSTRACT:"Golcadomide" OR TITLE:"CC-99282" OR ABSTRACT:"CC-99282" OR TITLE:"BMS-986369" OR ABSTRACT:"BMS-986369") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Golcadomide, not a curated reading list.
Shares A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL), Follicular lymphoma.
Shares IKZF1 (Ikaros), IKZF3 (Aiolos), Ubiquitin-proteasome system & protein homeostasis, PROTACs & molecular glues (targeted protein degradation).
Shares IKZF1 (Ikaros), IKZF3 (Aiolos), IRF4.
Shares IKZF1 (Ikaros), IKZF3 (Aiolos).
Shares PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma, Diffuse large B-cell lymphoma.
Shares IKZF1 (Ikaros), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Ubiquitin-proteasome system & protein homeostasis, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Ubiquitin-proteasome system & protein homeostasis, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.